Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment

Abnormal adhesion of red blood cells to the endothelium and the production of cytokines and vasoactive substances, such as endothelin-1 contribute to the pathogenesis of microvascular occlusion in sickle cell disease (SCD), even during the steady state. Endothelin-3 (ET-3) is a vasoconstrictive agen...

Full description

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 89; no. 3; pp. 360 - 361
Main Authors:	Makis, AC, Hatzimichael, EC, Kolios, G, Bourantas, KL
Format:	Journal Article
Language:	English
Published:	Italy 01-03-2004
Subjects:	Adult Anemia, Sickle Cell - blood Anemia, Sickle Cell - drug therapy Antisickling Agents - therapeutic use Endothelin-3 - blood Female Humans Hydroxyurea - therapeutic use Male Middle Aged
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abnormal adhesion of red blood cells to the endothelium and the production of cytokines and vasoactive substances, such as endothelin-1 contribute to the pathogenesis of microvascular occlusion in sickle cell disease (SCD), even during the steady state. Endothelin-3 (ET-3) is a vasoconstrictive agent, which has not yet been studied in SCD.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	0390-6078 1592-8721